ACM Biolabs
Singapore, Singapore· Est.
A Singapore biotech delivering thermostable polymer‑lipid nanoparticles for mRNA vaccines and oncology immunotherapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $15M
AI Company Overview
A Singapore biotech delivering thermostable polymer‑lipid nanoparticles for mRNA vaccines and oncology immunotherapies.
OncologyInfectious DiseasesImmunology
Technology Platform
The ACM Tunable Platform (ATP™) is a polymer‑lipid hybrid nanoparticle that is thermostable and can be tuned to encapsulate mRNA, oligonucleotides, proteins, and small molecules, enabling non‑viral delivery with enhanced stability and efficacy.
Opportunities
Thermostable mRNA delivery can unlock vaccine access in low‑resource markets, while the modular platform enables rapid expansion into diverse oncology and infectious disease indications.
Risk Factors
Regulatory approval of a novel non‑viral delivery system may be challenging, and competition from established lipid‑nanoparticle platforms could limit market adoption.
Competitive Landscape
ACM differentiates itself through thermostability and payload versatility, competing with lipid‑nanoparticle leaders and emerging polymer‑based delivery firms, but must prove clinical superiority to gain market share.